Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

Novo Nordisk’s newest insulin receives EMA approval; expected to launch in the first half of 2017
Research presented at ADA’s 2017 conference shows exciting advances in a host of diabetes drugs – including heart benefits, improved glucose control, lower cholesterol,...
Recall applies to sets manufactured before April 2017; Medtronic is replacing old sets that have a risk of insulin over-delivery
New apps and software updates from mySugr, Insulia, One Drop, as well as food and weight loss apps
A currently-enrolling trial is investigating a new arthritis medication along with type 2 diabetes drug Victoza, aiming to preserve insulin production in people with...
Despite neutral heart outcome study results, the FDA added a warning for those at risk of heart failure
By Maeve Serino and Adam Brown Learn about what’s new and what’s coming soon in Smart Pens, automated insulin delivery, pumps, and more Diabetes technology moves fast,...
A decision on Novo Nordisk’s faster-acting mealtime insulin is expected in late 2017; also launched in Canada, Germany, and the UK, and coming soon to more European...
Sanofi’s insulin adjustment app to help people with type 2 diabetes optimize once-daily long-acting basal insulin is now available for Apple and Android devices
Health Canada has approved the once-daily insulin for adults with type 1 and type 2 diabetes
Continuously delivers GLP-1 agonist for 3-6 months; FDA decision is expected by the end of 2017
CVD-REAL study showed SGLT-2 inhibitors reduce the risk of hospitalization for heart failure in over 300,000 people with type 2 diabetes
Research reveals improved A1c and weight loss benefits for people with type 1 diabetes on sotagliflozin, but a slightly increased risk of DKA
Trial results testing sotagliflozin and Farxiga in type 1 diabetes show greater A1c lowering and weight loss, plus continued conversation about small risk of DKA
The FDA officially approves the new, expanded indication for people with type 2 diabetes
Studies highlight reduced hypoglycemia risk for people with type 2 diabetes who switch to “next-gen” basal insulins Toujeo or Tresiba
A new basal insulin is on the horizon in the US with Merck’s LUSDUNA Nexvue, but launch timing obscured by ongoing lawsuit
Faster version of Novo Nordisk’s NovoLog approved in the US for type 1 and type 2 diabetes, launch expected as early as end of 2017
Lilly announces new program, in partnership with Express Scripts, to provide insulin directly to people with diabetes and high out of pocket drug expenses
Express Scripts recently announced the launch of Inside Rx, a discount prescription program with savings ranging from 16% to nearly 80% for insulin and other diabetes...